2020CSCO丨郭军教授：中国黑色素瘤研究初具蓝图，未来需多中心协同推进
盘点2020｜斯璐：黑色素瘤治疗进展盘点
解码黑色素瘤青年探索者斯璐：她也曾想过放弃
●●●Original melanoma of China●●●
2005-至今国际会议大会发言（除SMR外）共计8项（其中ASCO 4项，AACR 1项，AACR Melanoma 1项，ESMOAsia 2项）
2012ASCO: Phase II randomized study of high-dose interferon alfa-2b (HDI)versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma（8506）2016ESMOAsia: The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients from china（404O）
2017ESMOAsia: Phase Ic trial of intralesional OrienX010 oncolytic viral therapy into liver metastases among melanoma patients（379O）
2019AACR Melanoma: The landscape of mucosal melanoma：a long way to go
2020ASCO: Overall survival and biomarker analysis of a phase Ib combination study of toripalimab，a humanized IgG4 mAb against programmed death-1（PD-1）with axitinib in patients with metastatic mucosal melanoma（10007）2021AACR: Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study（CT035）2021ASCO: Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial（9511）2021ASCO: A phase 2 clinical trial of neoadjuvant anti-PD-1 ab（Toripalimab）plus axitinib in resectable mucosal melanoma（9512）
本站仅提供存储服务，所有内容均由用户发布，如发现有害或侵权内容，请
点击举报。
